DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
05 April 2018 - 9:15PM
DiaMedica Therapeutics Inc. (the “
Company”)
(TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of
Mr. Scott Kellen as Chief Financial Officer and Corporate
Secretary.
“We are extremenly pleased to welcome Scott to
DiaMedica’s executive team,” notes Mr. Rick Pauls, President and
CEO. “Scott brings a strong background in financial strategy and
reporting, previously working in various roles with several
publicly traded healthcare companies, and his deep understanding of
the financial needs of development stage biotechs will prove
invaluable to us as we execute on our clinical development plans
and next phases of growth.”
Mr. Kellen is a highly qualified senior
executive with corporate board experience. He has held positions as
Chief Operating Officer and Chief Financial Officer within publicly
traded healthcare companies, most recently as CFO for Sun Bio
Pharma. In addition to the positions he has played, Mr. Kellen has
significant experience with capital formation, public company
reporting and corporate governance.
Mr. Kellen has held a Certified Public
Accountant certificate, and graduated summa cum laude from the
University of South Dakota with a Bachelor of Science in Business
Administration. He stated, "It is a tremendous opportunity to
become a part of the DiaMedica executive team at such an exciting
time and stage of development." Mr. Kellen further commented, "I'm
eager to be joining the team as we continue to refine the corporate
strategy and advance the DM 199 pipeline."
The company today also announced the resignation
of David Gurvey as VP finance. On behalf of the Board of
DiaMedica, the Company would like to extend its warmest gratitude
to David Gurvey for his valuable contributions to DiaMedica
and wishes him the best in his future endeavors.
About DiaMedica Therapeutics
Inc.
DiaMedica Therapeutics is a clinical stage
biopharmaceutical company focused on developing novel treatments
for neurological and kidney diseases. DiaMedica’s shares are listed
on the TSX Venture Exchange under the trading symbol “DMA” and on
the OTCQB under the trading symbol “DMCAF”. For more information,
please visit www.diamedica.com. Follow us on
social media – Twitter,
LinkedIn.
For further information, please
contact:Paul Papi Vice President of Business Development
DiaMedica Therapeutics Inc. Two Carlson Parkway, Suite 260
Minneapolis, MN Phone: (617) 899-5941 info@diamedica.com
Tweet this!
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of the contents of this press release.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024